| Biotechnology Industry | Healthcare Sector | Oludare Odumosu CEO | SET Exchange | TH8980010004 ISIN |
| AU Country | 8 Employees | - Last Dividend | - Last Split | 28 Jul 2003 IPO Date |
Zelira Therapeutics Limited is a bio-pharmaceutical company that specializes in the research, development, and commercialization of cannabinoid-based medicines. The company has a focus on treating a wide range of medical conditions through its research and development efforts in Australia and the United States. The company was initially known as Zelda Therapeutics Limited but underwent a name change to Zelira Therapeutics Limited in December 2019. Since its inception in 2003, Zelira Therapeutics has established itself as a leader in cannabinoid-based therapies, boasting a diverse portfolio of products across various therapeutic areas. The company's headquarters are located in Perth, Australia, solidifying its presence both domestically and internationally.
Zelira Therapeutics offers a range of cannabinoid-based formulations under the HOPE brand. These formulations are available in Australia, Washington, Pennsylvania, and Louisiana, designed to meet the needs of patients suffering from various medical conditions. The HOPE brand represents the company's commitment to providing innovative and effective treatments.
Zenivol is a cannabinoid-based medicine developed by Zelira Therapeutics specifically for the treatment of chronic insomnia. This product signifies the company's effort to address a significant and often difficult-to-treat condition, showcasing their expertise in leveraging cannabinoids for therapeutic purposes.
Zelira Therapeutics also offers over-the-counter products, further expanding its reach beyond prescription medications. These include: